The slippery slope of the human gene editing debate
By John Evans,
Oxford University Press Blog
| 09. 22. 2020
The ethical debate about what is now called “human gene editing” (HGE) began sixty years ago. At the time, eugenicist scientists wanted to use new knowledge about the structure of DNA to modify humans—to perfect the human species by making us more healthy, musical, intelligent, and generally virtuous. A consensus later formed that gene editing on individuals to remove disease is acceptable, but nobody should try to change the human species. This is known as the somatic (individual) vs. germline (species) distinction, and it served as a moral limit on HGE for 50 years. A few years ago the news broke that a Chinese scientist had facilitated the creation of children who have been genetically modified so their descendants would also be modified—germline HGE. The germline limit now seems to be gone. Are there any limits left?
The HGE debate, like many bioethical debates, is set up like a slippery slope. At the top is an act universally considered morally virtuous (point A). Stepping on the slope at the top makes the act a little bit further down the slope...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...